1. Home
  2. Browse Decisions
  3. F.Supp.2d
  4. 789 F.Supp.2d
  5. 789 F.Supp.2d 1 (2011)
 

MYLAN PHARMACEUTICALS v. U.S. FOOD AND DRUG ADMIN.

Civil Action No. 11-566 (JEB).

789 F.Supp.2d 1 (2011)

MYLAN PHARMACEUTICALS INC. and Matrix Laboratories Ltd., Plaintiffs, v. UNITED STATES FOOD AND DRUG ADMINISTRATION, Defendant, and Ranbaxy Laboratories Limited, Intervenor-Defendant.

United States District Court, District of Columbia.

May 2, 2011.

Attorney(s) appearing for the Case

Douglas B. Farquhar, Karla Lynn Palmer, Hyman, Phelps & McNamara, P.C., Washington, DC, for Plaintiffs.

Andrew E. Clark, Gerald Cooper Kell, U.S. Department of Justice, Office of Consumer Litigation, Washington, DC, for Defendant.

Carlos T. Angulo, Carmen Mercedes Shepard, Alexandra W. Miller, Zuckerman Spaeder, LLP, Washington, DC, for Intervenor-Defendant.

MEMORANDUM OPINION*

JAMES E. BOASBERG, District Judge.

The Food and Drug Administration is currently reviewing the application of Ranbaxy Laboratories to have temporary exclusive rights to market a generic drug. Matrix Laboratories, a competitor that has a subsequent application pending for the same drug, eagerly wishes to know the result of Ranbaxy's application. In fact, Matrix and its distributor Mylan Pharmaceuticals...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases